Solid Phase Antigen Luminescent Immunoassays (SPALT) for the Determination of Insulin, Insulin Antibodies and Gentamicin Levels in Human Serum by Wood, W. G. et al.
Wood, Fricke, v. Klitzing, Strasburger and Scriba: SPALT assays for gentamicin, insulin and insulin antibodies in serum 825
J. Clin. Chem. Clin. Biochem.
Vol. 20,1982, pp. 825-831
Solid Phase Antigen Luminescent Immunoassays (SPALT) for the Determination of Insulin,
Insulin Antibodies and Gentamicin Levels in Human Serum
ByK> G. Wood,H.Fricke
Klinik für Innere Medizin (Direktor: Prof. Dr. P. C. Scriba)
L. von Klitzing
Klinisch-Experimentelle Forschungseinrichtung im Transitorium, Medizinische Hochschule Lübeck
C. J. Strasburger and P. C. Scriba




(Received April 20/July 27,1982)
Summary: We describe an interesting and novel alternative to cqriventional immunoassay techniques for the measure-
ment of antigens aild antibodies in body fluids.
The label used for all assays is a pyruvate kinase-IgG conjugate of the relevant second (species-specific) antibody. All
assays follow the same principle in which a solid phase antigen is used to adsorb unreacted first (substance-specific)
antibody follöwing a conventional antibpdy-antigen reaction in a liquid phase. After washing, the solid phase antigen-
first antibody is allowed to react with the läbelled second antibody. The solid phase is then washed and the pyruvate
kinase bound to the solid phase is used to generate ATP which is measured kinetically in a luminometer.
Assays are described for insulin, insulin antibodies and gentamicin to demonstrate both the versatility and sensitivity
of this type of assay.
The kisiilin assay häd ä löwer detection limit of unider 0.25 ) per tube and was comparable with the radioimmuno-
assay used for föutine purposes both in sensitivity and reproducibility. The insulin antibody assay correlated well with
the radiometric aeterminatjon used rputinely in the laboratory.
The gentamicin assay correlated well with the routine commercial radioimmunoassay and also had comparable co-
efficients of Variation.
In all cases, the faiter- and inträ-assay Variation was under 10% iri the ränge of interest.
)
Solid Phase Antigen Lumineszenzimmünoassays (SPALT) für die Bestimmung von Insulin, Insulin-Antikörper und
Gentamicin im menschlichen Serum
Zusammenfassung: Es wird eine Alternative zu der herkömmlichen Immunoassay-Technik für die Bestimmung von
Antigenen und Antikörpern in biologischen Flüssigkeiten beschrieben.
Allen Assays liegt das gleiche Prinzip zugrunde, wonach zunächst eine Antigen-Antikörper-Reaktion abläuft. Durch
nachfolgende Zugabe des gleichen, jedoch an einen festen Träger gebundenen Antigens werden die noch freien Anti-
körper abgefangen. Djese „ersten" Antikörper stellen das Antigen eines „zweiten" Antikörpers (Pyruvatkinase-IgG-
Konjugat) dar: hiermit ist es mögjich, eine dem „ersten" Antikörper entsprechende Menge Pyruvatkinase an das
Trägermaterial zu binden.
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In dem anschließenden Bestimmungsansatz bildet dieses Enzym ATP, dessen Synthese-Kinetik in einem Luminometer
gemessen wird. An den Beispielen der Insulin-, Insulin-Antikörper- und Gentamicinbestimmungen wird die Empfindlich-
keit und die Vielseitigkeit dieser Methode demonstriert.
Bei der Insulinbestimmung liegt die Nachweisgrenze unter 0,25 im Ansatz und ist somit vergleichbar mit dem her-
kömmlichen Radioimmunoassay, sowohl was Empfindlichkeit als auch die Reproduzierbarkeit betrifft. Das entspre-
chende gilt auch für die Insulin-Antikörper- und Gentamicinbestimmung.
Die Variationskoeffizienten, sowohl innerhalb einer Meßreihe als auch von Tag zu Tag, liegen deutlich unter 10%.
Introduction
The use of a solid-phase covalentiy-coupled antigen
opens up a new vista for immunpassays which use a
single "tracer", namely a labelled second antibody
(1,2). The label used ürthis series of experiments was
a pyruvate kinase-IgG conjugate prepared in an ana-
logous way to a transferrin conjugate, the method
having recently been published (3).
The choice of a proteohormone, therapy-induced
antibodies and a Jiapten have been chosen to demon*
strate both the versatility and sensitivity of the System.
Activated cellulose was used äs the support for the anti-
gen after experiments with alternatives had led to
unsatisfactory results.
Not only the choice of assay buffer but also the choice
of wash solution influenced both the sensitivity and
unspecific binding of the assays.
The assays here described can be seen äs a further
development of luminescent immunoassays which can
be used routinely.
The use of such a System brings potential problems, ·
especially in the determination of haptens, where the
conjugate used äs immunogen must be known. The
conjugate-protein (e.g. bovine serum albumin) must
not be used either to saturate free binding sites on the
matrix, or äs a component of the assay buffer.
The positive effect of such an assay System is that
potential interfering compounds (e.g. sodium azide äs
preservative) are removed from the System before the
label comes into contact with the first antibody-
antigen complex.
The assays are comparable with radioimmunoassays
both in sensitivity and in precision, and are not limited
by problems of molecular weight or quenching äs are
certain chemiluminescent assays (4).
Materials and Methods
Materials
Donkey-anti-rabbit-IgG and rabbit-anti-guinea pig-IgG antisera
were purchased from Wellcome, Burgwedel, FRG.
Pyruvate kinase was purchased from Boehringer-Mannheim,
Mannheim, FRG., or from Sigma, Munich, FRG.
Microcrystalline cellulose, m-maleimidöbenzpyl-N-hydroxysuc*
cinimide, adenpsine diphosphate (ADP), phosphoenol pyruvate,
bovine and porcine insulin were obtained from Sigma, Munich,
FRG.
Sodium metaperipdäte, sodium borqhydride, sodium cyano-
bpfohydride and all buffer reagents were purchased from
Merck, Darmstadt, FRG. the antibodies tp insulin were
donated by Wellcome, Burgwedel, FRG. The gentamicin anti-
bodies were raised in rabbits in the hospital animal house.
The luminometer (LKB 1250), ATP^mpnitoring reagent and
accessories were donated by LKB, Düsseldorf, FRG and WaUac
Oy, turku, SF.
Cellulose activation and coupling of antigens
The activation pf the cellulpse with sodium metaperiodate,
with the subsequent coupling and stabüisation of the insulin
and gentamicin was carried out äs already published for trans-
ferrin (3).
Assay of insulin in serum
Table l shows the various assay schemes for the insulin deter-
mination. Figure l shows the insulin assay äs an example of the
solid phase antigen luminescent technique (SPALT) here
described.
Assay of serum gentamicin levels
Table 2 shows the competitive and sequential SPALT assays
for the determination of gentamicin''in-serum. In the case
of the competitive assay, the solid-phase gentamicin must first
be titrated to ensure that the correct amount of solid-phase
antigen is present in the System.
Determination of insulin^antibodies in human serum
Table 3 shows the incubation scheme for this assay. As can be
seen, one can test the specificity of the auto-antibodies by
varying the solid-phase antigen. In this case, the solid phase
antigen is either bovine insulin or porcine insulin. For a general
antibody detection, a mixture of tne two solid-phase antigens
can be used. The determination of insulin antibodies follows
the principle of the RAST-tests from Pharmacia (Uppsala, S).
Comparative assays
The assays used äs comparison for the insulin and gentamicin
determinations were radipimmunpassays, (Insulin - INSIK 3
CIS (Isotopendienst West, Dreieich, FRG) and Gentamipin
RIA - Diagnostic Products Corporation, (Hermann Biermann,
Bad Nauheim, FRG.)).
The detection pf insulin antibodies was perf ormed by allowing
the patient serum react with radioactive insulin, followed by
precipitation pf the immunoglobulins with polyeihylene glycol
(200 g/l).
Preparation of the labelled second antibody
The conjugation of the immunogiobulin fraction of the second
antibody with pyruvate kinase was caniectyout using the method
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Tab. 1. The fivc insulin assay incubation schemes used in this study
Assay
Serum/standard volume (μΐ)
Guinea pig-anti insulin (1:20000) (μΐ)
Assay buffer (μΐ)
Incubation time (h)/tempeiature (°C)
Microcry stalline cellulose-insulin (dilution 1:100) in assay buffer (μΐ)

































In all assays, the microcrystalline cellulose was washed twice with l ml wash buffer foilowed by centrifugation at 3000# for 10 minutes
at4°C.
Pyruvate-kinase labelled anti-guinea pig IgG - (1:100 dilution) (μΐ)











The wash procedure was repeated s described above and the washed cellulose-bound pyruvate kinase labelled second antibody
used to generate ATP from ADP and phosphoenai pyruvate in the presence of a flrefly luciferase/luciferin preparation. The ATP-
production was measured kinetically in a luminometer s already described for the serum transferrin assay (1).
RT - ambient temperatuie, in these experiments 18-21 C.




Standard/serum - (l: 100 dilution with 100 100
assay buffer) (μΐ)
Rabbit-anti-gentamicinKl: 1000 dilution)^!) 100 100
Cellulose-gentamicin (l: 100 dilution) (μΐ) 20 0
Incubation time for both assays 30 min at ambient temperature
on a vibrator.
Cellulose-gentamicin (1:100 dilution) (μ!) Ο 100
Incubation time (min) 0 30




Pyruvate kinase labelled anti-rabbit IgG
(1:50 dilution) (μΐ)
Incubation time (min)
Again, both assays were subjected to the same washing step s
in table l, foilowed by the same detection method for the
ATP-production.
All incubation Steps were carried out at room temperature on
a vibrator in order to keep the cellulose suspended.
Fig. 1. SPALT principle 1. This shows a conventional ntibody-
antigen reaction which takes place in a liquid phase.
SPALT principle 2. The unieacted antibody is allowed to
react with an excess of solid phase antigen.
SPALT principle 3. After washing and centrifugation, %
the solid phase is allowed to react with the labelled second
antibody.
SPALT principle 4. The solid phase is then washed once
more and then used to generate ATP, which is allowed
to react with the luciferin-luciferase system to generate
This is the scheine for the sequential asssy . The competi-
tive assay uses less solid phase antigen and combines the
first two steps.
^^ Solid phase antigen
•^ Antigen in the sample
>- First antibody
Pyruvate kinase labelled second antibody
ofKitagawa &Aikawa (5), in which the heterobifunctional
reagent /H-maleimidobenzoyl-N-hydroxysuccinimide acted s a
linking agent. The immunoglobulin fraction of the respective
second antibody was prepared by precipitation with polyethyl-
ene glycol (200 g/l), foilowed by resuspension in 0.15 mol/1
sodium chloride. This precipitation and resuspension was
repeated, the resulting solution of immunoglobulins being
coupled in an analogous way to transferrin (3) to the pyruvate
kinase.
Separation of the reaction mixture was performed using an
ltrogel A6 column (100 X 2.5 cm), fractions containing both
pyruvate kinase and immunological activity being pooled,
portioned and lyophilised.
Preparation of the assay buffer and wash Solutions
The assay buffer used for all assays consisted of the following
components:
0.05 mol/1 TRIS-HCl, 2 g/l bovinc serum albumin, 0.01 mol/l
potassium chloride adjusted to pH 7.8.
J. Clin. Chem. Clin. Biochem. / Vol. 20,1982 / No, 11
828 Wood, Fricke, v. Klitzing, Strasburger and Scriba: SPALT assays for gentamicin, insuün and insülin antibodies in serum
The wash solution consisted of equal volumes of assay buffer
and J .5 mol/1 potassium Chloride.
The buffer used in the light-generation step was identical with
that used in the transferrin assay already published, (3), äs was
the concentration of the light-initiation mixture.
Quantification of the immunoreactive solid-phase
antigen
Dilutions of well-washed solid-phase antigen were assayed in
the normal radioimmunoassay in tlie same way äs serum
samples. The removal of antibody from the reaction mixture
by the solid-phase antigen resulted in a lower tracer binding in
the liquid-phase. This method allows a good estimate of the
degree of immunoreactive antigen to be made.
Tab. 3. Insulin antibody SPALT assay scheme, shpwing two alter-
native methods of obtaining a "titer'* measurement.
Method l
100 cellulose-insulin (bovine or porcine) 1:100 dilution in
assay buffer.
assay buffer.
Incubate 18 h a t 4 °C
Wash äs in the insülin and gentamicin assays.
100 sheep-anti-human IgG^-pyruvate kinase 1:100 dilution in
assay buffer.
Incubate 2 h at room temperature on a vibrator.
Wash äs above and measure the ATP-production äs in the insülin
and gentamicin assays.
The results are expressed äs the ratio between the signal from
the serum to be measured to that in the negative coiitrol.
Values over 1.50 are to be regarded äs positive.
Method 2
The method is principally'the same äs above, except that the
serum to be tested is diluted with negative control serum in
dilution Steps l part serum + 9 parts negative control serum,
covering the ränge 1:10 to 1:10000.
This allows an estimate of the antibody "titer". When the ratio,
äs described above, falls under 1.50, the serum or serum dilution
is regarded äs negative.
The factor 1.50 encompasses a + 4 Standard deviation ränge above
the negative control value determined from 100 blood donors.
2700
Results and Discussion
Figure 2 shows a Standard curve for insülin and table 4
the results from the different incubation Scheines, the
latter being expressed in tabular form. Figures 3 and 4
show the gentamicin sequential and competitive assays.
Table 5 shows correlation datä between the routine
radioimmunoassays and the corresponding SPALT
assays for both gentamicin and insülin.
Table 6 shows comparispns between the insulin-antibody
assays, using sera chosen specially because of the absence
of antibodies to both bovine and porcine insülin. Norm-
ally, insülin antibodies, when present, react with both











Fig. 2. This shows a Standard curve for insülin using assay E
in table 4 äs an example. The curve is plotted on semi-
log co-ordinates.































































































In assays A & C the cellulose was transferred to a> fresh tube
before the ATP assay was carried out.
The assay codes are the same äs in table 1.
All values above are corrected for unspecific binding.
Assay E was chosen äs the "routine'* assay, to cover the ränge
10-200mU/l.
Table 7 shows precision data from both RM ändÄPALT
assays.
:"/
As a result of the data in tables 5 arid 7, specific recövery
experiments were considered to be superfluous^ äs the
results from both methods are seen to be the same.
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Tab. 5. Correlation between the routine RIA-methods and the




































The regression equation y = a + bx was used, RIA values being
entered äs in each case.
Gentamicin






Fig. 3. This shows a gentamicin Standard curve for the sequential ^x'














Standard error of the estimate y from
95%confidence 0.379 7.68
limits




The data used was normally distributed - i.e. was not signific-
antly different from a Gaussian distribution curve.
*) The coefficient of Variation was used äs the measure of dis-
persion of the values used in the calculations above.
Tab. 6. Compaiison of radio- and luminescent assay data for the
detection of insulin antibodies äs described in table 3,
methpd 1.
0.1 1 2 4
Gentamicin [mg/l]
8 16
Fig. 4. This shows an example of tho competitive gentamicin assay
described in table 2. The light geneiation is mueh slower
than in flgure 3 due to the löwer amount of solid-phase
antigen used.
Radioassay using 125I-labelled porcine insulin äs antigen.
P-LIA = SPALT assay using solid phase porcine insulin.
B-LIA= SPALT assay using soüd phase bovine insulin.
These patients were carefully selected for antibodies which
were specific fpr only one insuHn-variety. Patient 1-763 had
antibodies which reacted with both porcine and bovine insulin.
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Tab. 7. Relevant statistical data comparing the performancc of the RIA and SPALT assays for insulinand*gentamicin in serum.
Precision profile, shows the distribution of the coefficients pf Variation for the mean of duplicate vaiues covering the ränge between






Percentiles have been used äs the data were not normally distributed. The vaiues undei the percentile headings represent the precision
in percent lying equal to or below the percentile value. For example, for the gentamicin SPALT assay 50% of all precision vaiues lie
under5.6%.





















































































































The Standards used in both methods were identical. .
*) ns/na denotes number of samples/number of assays.
The introduction of a solid-phase antigen assay is in prin-
ciple nothing new, äs this type of immobilisation of
antigens has formed part of the in-vitro laboratory dia^
gnosis of hepatitis and specific allergies (RAST test). The
use of an immobilised antigen and an iodinated second
antibody äs "universal label" has also been recently
published for haptens in a competitive assay (1,2). The
novelty of the SPALT is its capability to measure both
proteins and haptens without radioactivity, and with
a sensitivity equal to that obtainable in radioimmuno-
assay. The sensitivity of the SPALT insulin assay, defined
äs the lowest detectable concentration or the value read
off the Standard curve using a coünt-rate 2 Standard
deviations lower than the mean zero Standard count-
rate, is under 5 fmol per tube (equivalent to < 3 mU/1)
for the routine assay using a 100 serum sample.
The use of a sequential assay technique has all the
advantages of the immunoradiometric type of assay
inasmuch äs an excess of solid-phase antigen cän be used,
äs well äs an excess of labelled second antibody. The
precision of the assay depends to a large extent upon
the first step of the assay, i.e. the pipetting of sample
and first antibody. The form of the Standard curve is
similar to that of a conventional radioimmunoassay,
i.e. maximal Signal at minimal analyte concentration,
so that the Signal at this concentration corresponds to
an almost 100% "bound tracer Signal".
The use of a second antibody label, apart from its
universal application to all assays using a common-
species first antibody, means that the reagents used "in
the first reaction step may contain preservatives nörm-
ally found in radioimmunoassay systenis, e.g, sodium
azide, äs these are femöved fröm the System duririg the
first wash step, i.e. before additipn of the pyruvate
kinase labelled seepnd antibody. Problems can arise
when a choice of preservative for the second antibody
solütion has to be mäde. Addition of antibiötics to
the reconstituted label appear to häve no deleteriöüs
effects, bearing in mind that the choice of antibiotic
may be critical, äs in the .gentamicin assay for example.
The insulin assay here described shows that the optimal
signal to blank ratios are obtained with assay E, that is,
an assay with a three day incubation, although accept-
able sensitivity and precision can be obtained using
shofter assay times. The optimal design lies in the
choice of both first and seeond antibodies, and also upon
whether the antibodies are purified before use, (1). The
general opinion nqw appears to favour the use of mpnp-
clonal second antibody for labelling, not or^ly because pf
specificity, but also becäüse öf the punty öf the reägent
which cän be obtained (Voller, A. & Hunter> W> M.,
personal Communications).
The gentamicin assay can either be perfofmed äs a
sequential or competitive assay, the latter resulting
in a quicker assay, but lower signal äs the solid-phase
antigen must be present at much lower concentrations.
The use of excess reagents allows for a greajer margui
of error in pipetting and is reflected in the precision
obtained for the assays here described^Using a specific
solid-phase insulin allowed the detection of mono^
spefcific antibodies to either porcine or bovine insulin
in a small number of patients, althopjgh, äs stated
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above, most patients had antibodies which bound both.
An important criticism of the SPALT assay äs described
here, is the need for thorough washing of the solid-phase
between Steps. Before such an assay can have a chance,
commercially speaking, a solid-phase must be developed
which is easy to handle, and if possible, easy to wash
without having to use a centrifuge-step. Preliminary
results show that in the case of larger antigens such äs
thyroxine binding globulin (TBG), treated glass balls
can replace microcrystalline cellulose äs a support to
which the TBG is covalently coüpled. Whether a sünilar
technique can be used for haptens is still to be seen,
although the results ofStafford and Kilgallon (l, 2) show
that it should be possible.
Superficial studies show that there is nothing to stop
other labelled second antibody preparations being used
in a solid phase antigen technique. Replacement of
pyruvate kinase by azoluminol leads to a SPALT
assay using a chenülumjnescent detection System (6).
This type of assay has also been used to measure genta-
micin using an identical assay System äs here described.
Peroxidase labelled second antibody has been used to
detect the presence of gonococcal antibodies using a
gonococcus extract covalently attached to micro-
crystalline cellulose (Wood, unpublished data). Although
bilirubin in concentrations up to five times the upper
limit of the normal ränge have häd no effect on the
results, the possibility exists that haemolytic serum may
contain sufficient pyruvate kinase to affect the results.
To remove such effects, pyruvate kinase Inhibitors can be
added to the first incubation Step, provided that the con-
centrations used allow a complete removal from the
System before the second antibody incubation step.
Lipaemic sera affect the SPALT in the same way äs a
normal radioimmunoassay inasmuch äs the large
amounts of fats inhibit the antibody-antigen reactions,
äs well äs swamping the solid-phase antigen.
In the search for a more acceptable solid-phase for
haptens, it cannot be excluded at this stage that an alter-
native to pyruvate kinase may have to be found, äs it
appears that the second antibody-pyruvate kinase
may be sterically hindered from binding to the first
antibody-antigen complex when using a high-density
solid-phase such äs glass or activated Teflon. An attrac-
tive alternative, at least on paper, is adenylate kinase
(EC 2.7.4.3) because of its low molecular weight
(21000) and stability against heat and pH-changes.
As with all new techniques, the impact of the luminesc-
ence immunoassays äs described here depend upon the
availability of automated luminometers, äs well äs
robust commercial kits.
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